Zai Lab Ltd- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Zai Lab Ltd 公司

Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.

Zai Lab Ltd简介



公司代码ZLAB

公司名称Zai Lab Ltd

上市日期Sep 28, 2020

CEODu (Ying)

员工数量1869

证券类型Depository Receipt

年结日Sep 28

公司地址Building B, 899 Halei Road, Pudong

城市SHANGHAI

上市交易所NASDAQ OMX - NASDAQ BASIC

国家China

邮编201203

电话862161632588

网址https://www.zailaboratory.com/

公司代码ZLAB

上市日期Sep 28, 2020

CEODu (Ying)

Zai Lab Ltd公司高管



名称

名称/职务

职务

持股

持股变动

Dr. John David Diekman, Ph.D.

Lead Independent Director

99.77K

+10831.00%

Mr. Joshua L. Smiley

President, Chief Operating Officer

86.60K

+10000.00%

Mr. William David (Bill) Lis

Independent Director

35.11K

-2983.00%

Dr. Yajing Chen, Ph.D.

Chief Financial Officer

17.44K

-240.00%

Dr. Ying (Samantha) Du, Ph.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

--

Ms. Leung (Nisa Bernice) Wing-Yu

Independent Director

--

Mr. Peter Karl Wirth, J.D.

Independent Director

--

Mr. Leon Oliver (Lonnie) Moulder, Jr.

Independent Director

--

Mr. Frazor Titus Edmondson, J.D.

Company Secretary, Chief Legal Officer

--

Mr. Scott W. Morrison, CPA

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Dr. John David Diekman, Ph.D.

Lead Independent Director

99.77K

+10831.00%

Mr. Joshua L. Smiley

President, Chief Operating Officer

86.60K

+10000.00%

Mr. William David (Bill) Lis

Independent Director

35.11K

-2983.00%

Dr. Yajing Chen, Ph.D.

Chief Financial Officer

17.44K

-240.00%

Dr. Ying (Samantha) Du, Ph.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

--

Ms. Leung (Nisa Bernice) Wing-Yu

Independent Director

--

收入明细

单位: USD更新时间: 1月6日周二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

业务USD

名称

营收

占比

ZEJULA

42.43M

36.78%

VYVGART

27.73M

24.03%

NUZYRA

15.43M

13.38%

Optune

12.66M

10.97%

QINLOCK

8.90M

7.72%

其他

8.21M

7.12%

地区USD

名称

营收

占比

China (Mainland)

116.09M

0.00%

业务

地区

业务USD

名称

营收

占比

ZEJULA

42.43M

36.78%

VYVGART

27.73M

24.03%

NUZYRA

15.43M

13.38%

Optune

12.66M

10.97%

QINLOCK

8.90M

7.72%

其他

8.21M

7.12%

股东统计

更新时间: 2月7日周六

持股股东

股东类型

持股股东

占比

Capital World Investors

5.39%

Fidelity Management & Research Company LLC

3.79%

Norges Bank Investment Management (NBIM)

3.41%

ClearBridge Investments, LLC

3.12%

RTW Investments L.P.

2.03%

其他

82.26%

持股股东

占比

Capital World Investors

5.39%

Fidelity Management & Research Company LLC

3.79%

Norges Bank Investment Management (NBIM)

3.41%

ClearBridge Investments, LLC

3.12%

RTW Investments L.P.

2.03%

其他

82.26%

股东类型

持股股东

占比

Investment Advisor

15.68%

Investment Advisor/Hedge Fund

12.47%

Sovereign Wealth Fund

3.58%

Hedge Fund

2.94%

Individual Investor

1.78%

Private Equity

1.44%

Venture Capital

1.12%

Research Firm

0.61%

Pension Fund

0.02%

其他

60.34%

机构持股



更新时间: 1月21日周三

报告期

机构数

持股数

持股占比

持股变动

2026Q4

280

37.42M

42.38%

--

2025Q4

370

44.73M

39.84%

-12.84M

2025Q3

372

46.61M

41.70%

-15.37M

2025Q2

394

60.58M

54.15%

-11.96M

2025Q1

453

59.51M

53.68%

-14.18M

2024Q4

446

60.80M

55.47%

-4.29M

2024Q3

439

51.45M

51.99%

-10.14M

2024Q2

454

47.04M

47.66%

-14.67M

2024Q1

465

46.22M

46.47%

-13.77M

2023Q4

497

46.31M

46.92%

-16.57M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Capital World Investors

6.08M

5.43%

+41.48K

+0.69%

Sep 30, 2025

Fidelity Management & Research Company LLC

4.28M

3.82%

-610.67K

-12.50%

Sep 30, 2025

ClearBridge Investments, LLC

3.52M

3.14%

-492.62K

-12.28%

Sep 30, 2025

RTW Investments L.P.

2.29M

2.05%

-3.25M

-58.62%

Sep 30, 2025

Janus Henderson Investors

2.05M

1.83%

-148.32K

-6.75%

Sep 30, 2025

Wellington Management Company, LLP

1.72M

1.53%

+341.49K

+24.80%

Sep 30, 2025

Frazier Life Sciences Management, L.P.

1.63M

1.45%

+319.18K

+24.40%

Sep 30, 2025

Baron Capital Management, Inc.

1.37M

1.22%

-216.57K

-13.64%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Tema Oncology ETF

1.67%

ALPS Medical Breakthroughs ETF

1.19%

Virtus LifeSci Biotech Products ETF

0.97%

Invesco Golden Dragon China ETF

0.58%

National Security Emerging Markets Index ETF

0.39%

iShares Biotechnology ETF

0.18%

Capital Group New Geography Equity ETF

0.15%

ProShares Ultra Nasdaq Biotechnology

0.12%

Invesco Nasdaq Biotechnology ETF

0.12%

ActivePassive International Equity ETF

0.03%

Tema Oncology ETF

占比1.67%

ALPS Medical Breakthroughs ETF

占比1.19%

Virtus LifeSci Biotech Products ETF

占比0.97%

Invesco Golden Dragon China ETF

占比0.58%

National Security Emerging Markets Index ETF

占比0.39%

iShares Biotechnology ETF

占比0.18%

Capital Group New Geography Equity ETF

占比0.15%

ProShares Ultra Nasdaq Biotechnology

占比0.12%

Invesco Nasdaq Biotechnology ETF

占比0.12%

ActivePassive International Equity ETF

占比0.03%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据